<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="article-commentary" dtd-version="3.0" xml:lang="EN">
  <front>
    <journal-meta><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="publisher">pmed</journal-id><journal-id journal-id-type="allenpress-id">plme</journal-id><journal-id journal-id-type="nlm-ta">PLoS Med</journal-id><journal-id journal-id-type="pmc">plosmed</journal-id><!--===== Grouping journal title elements =====--><journal-title-group><journal-title>PLoS Medicine</journal-title></journal-title-group><issn pub-type="ppub">1549-1277</issn><issn pub-type="epub">1549-1676</issn><publisher>
        <publisher-name>Public Library of Science</publisher-name>
        <publisher-loc>San Francisco, USA</publisher-loc>
      </publisher></journal-meta>
    <article-meta><article-id pub-id-type="doi">10.1371/journal.pmed.0050030</article-id><article-id pub-id-type="publisher-id">07-PLME-P-2227</article-id><article-categories>
        <subj-group subj-group-type="heading">
          <subject>Perspective</subject>
        </subj-group>
        <subj-group subj-group-type="Discipline">
          <subject>Infectious Diseases</subject>
          <subject>Virology</subject>
        </subj-group>
        <subj-group subj-group-type="System Taxonomy">
          <subject>HIV Infection/AIDS</subject>
          <subject>Infectious Diseases</subject>
          <subject>Sexually transmitted diseases</subject>
          <subject>Sexual Health</subject>
          <subject>Women's Health</subject>
        </subj-group>
      </article-categories><title-group><article-title>Antiretroviral Therapy for Prevention of HIV Infection: New Clues From an Animal Model</article-title></title-group><contrib-group>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Cohen</surname>
            <given-names>Myron S</given-names>
          </name>
          <xref ref-type="corresp" rid="cor1">
            <sup>*</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Kashuba</surname>
            <given-names>Angela D. M</given-names>
          </name>
        </contrib>
      </contrib-group><author-notes>
        <corresp id="cor1">* To whom correspondence should be addressed. E-mail: <email xlink:type="simple">mscohen@med.unc.edu</email></corresp>
        <fn fn-type="current-aff" id="n3">
          <p>Myron S. Cohen is J. Herbert Bate Distinguished Professor of Medicine, Microbiology, and Immunology and Public Health<bold>,</bold> the Director of the Institute for Global Health and Infectious Disease, and Chief of the Division of Clinical Infectious Disease, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America. Angela D. M. Kashuba is an Associate Professor in the School of Pharmacy, Director of the University of North Carolina Center for AIDS Research Clinical Pharmacology/Analytical Chemistry Core, and Director of the Verne S. Caviness General Clinical Research Center Analytical Chemistry Laboratory, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.</p>
        </fn>
      <fn fn-type="conflict" id="n2">
        <p> MSC declares that he has no competing interests. ADMK declares the following interests—consultancies: Bristol-Myers Squibb; grants received: Gilead Sciences, Pfizer.</p>
      </fn></author-notes><pub-date pub-type="ppub">
        <month>2</month>
        <year>2008</year>
      </pub-date><pub-date pub-type="epub">
        <day>5</day>
        <month>2</month>
        <year>2008</year>
      </pub-date><volume>5</volume><issue>2</issue><elocation-id>e30</elocation-id><!--===== Grouping copyright info into permissions =====--><permissions><copyright-year>2008</copyright-year><copyright-holder> Cohen and Kashuba</copyright-holder><license><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article ext-link-type="doi" id="RA1" page="e28" related-article-type="companion" vol="5" xlink:href="info:doi/10.1371/journal.pmed.0050028" xlink:title="Research Article" xlink:type="simple">
				<article-title>Prevention of Rectal SHIV Transmission in Macaques by Daily or Intermittent Prophylaxis with Emtricitabine and Tenofovir</article-title>
			</related-article><abstract abstract-type="toc">
        <p>The authors discuss the implications of a new study in macaques of antiretroviral pre-exposure prophylaxis regimens.</p>
      </abstract><funding-group><funding-statement> The authors are supported by the following grants from the National Institutes of Health: DK049381 (MSC) and AI54980 (ADMK). The authors are also supported by grant #P30 AI50410 from the University of North Carolina Center for AIDS Research. No specific funds were received for the preparation of this commentary.</funding-statement></funding-group><counts>
        <page-count count="3"/>
      </counts><!--===== Restructure custom-meta-wrap to custom-meta-group =====--><custom-meta-group>
        <custom-meta>
          <meta-name>citation</meta-name>
          <meta-value>Cohen MS, Kashuba ADM (2008) Antiretroviral therapy for prevention of HIV infection: New clues from an animal model. PLoS Med 5(2): e30. doi:<ext-link ext-link-type="doi" xlink:href="http://dx.doi.org/10.1371/journal.pmed.0050030" xlink:type="simple">10.1371/journal.pmed.0050030</ext-link></meta-value>
        </custom-meta>
      </custom-meta-group></article-meta>
  </front>
  <body>
    <sec id="s1">
      <title>Background</title>
      <p>The introduction of antiretroviral therapy (ART) in the early 1990s profoundly changed the face of HIV infection by improving survival rates [<xref ref-type="bibr" rid="pmed-0050030-b001">1</xref>]. But ART has equal potential for prevention, since it reduces the probability of HIV transmission from an infected person to their sexual partner(s). Although there have been no randomized controlled clinical trials on the subject, antiretroviral drugs are currently used in clinical practice for post-exposure prophylaxis after inadvertent occupational exposure (based on the results of a case control study [<xref ref-type="bibr" rid="pmed-0050030-b002">2</xref>]) or after sexual exposure to the virus [<xref ref-type="bibr" rid="pmed-0050030-b003">3</xref>]. Pre- and post-exposure prophylaxis (PrEP and PEP, respectively) have been used successfully to interrupt transmission of HIV from infected mothers to their babies [<xref ref-type="bibr" rid="pmed-0050030-b004">4</xref>].</p>
      <p>Investigators at the United States Centers for Disease Control and Prevention have conducted a series of studies in rhesus macaques to explore antiretroviral prophylaxis. First, they developed a rectal inoculation model using concentrations of simian HIV (SHIV) representative of human exposure [<xref ref-type="bibr" rid="pmed-0050030-b005">5</xref>]. Using this model, the investigators showed that tenofovir disoproxil fumarate (TDF, a nucleotide analogue reverse transcriptase inhibitor) delayed, but did not prevent, acquisition of SHIV in these animals (seven out of eight animals infected over 14 weeks) [<xref ref-type="bibr" rid="pmed-0050030-b006">6</xref>]. A new study in this issue of <italic>PLoS Medicine</italic> by Walid Heneine and colleagues [<xref ref-type="bibr" rid="pmed-0050030-b007">7</xref>] extends earlier observations and will certainly affect the direction of human clinical trials and public health policy.</p>
    </sec>
    <sec id="s2">
      <title>The Results</title>
      <p>In the new study, macaques were exposed to weekly rectal virus challenges for up to 14 weeks. The authors compared infections observed in 18 untreated macaques to infections in macaques that received a variety of antiretroviral PrEP regimens containing the nucleotide reverse transcriptase inhibitor emtricitabine (FTC) alone or in combination with TDF. With subcutaneous FTC alone (at a human-equivalent dose), four out of six animals became infected. With a combination of oral FTC and TDF at a dose equivalent to Truvada (FTC 200 mg + TDF 300 mg) in humans, two out of six animals became infected. With subcutaneous FTC and a supratherapeutic subcutaneous dose of tenofovir (given either daily or in a two-dose regimen before and after exposure), complete protection from infection was observed (none of the 12 animals became infected).</p>
      <p>For animals that became infected during treatment, the investigators noted that infection was delayed, and all animals had blunted acute viremia, suggesting the possibility of reduced immune damage during acute HIV infection [<xref ref-type="bibr" rid="pmed-0050030-b008">8</xref>]. Resistance to FTC was observed in two out of six animals that failed therapy.</p>
      <boxed-text position="float">
        <sec>
          <title/>
          <p>This Perspective discusses the following new study published in <italic>PLoS Medicine:</italic></p>
          <p>García-Lerma JG, Otten RA, Qari SH, Jackson E, Cong M, et al. (2008) Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med 5(2): e28. doi:10.1371/journal.pmed.0050028</p>
          <p>Using a repeat-exposure macaque model, Walid Heneine and colleagues find that pre-exposure prophylaxis with combination antiretroviral drugs provides protection against rectal challenge with a SHIV virus.</p>
        </sec>
      </boxed-text>
    </sec>
    <sec id="s3">
      <title>The Implications</title>
      <p>These and earlier animal studies have provided the basis for human clinical trials with PrEP. The observation of FTC resistance during therapy emphasizes the risk of PrEP to the individual and the community. PrEP continued in the face of unrecognized infection might be expected to promote replication of a resistant variant, which could be transmitted widely [<xref ref-type="bibr" rid="pmed-0050030-b009">9</xref>]. Tenofovir and FTC resistance are common in populations receiving ART, including in sub-Saharan Africa [<xref ref-type="bibr" rid="pmed-0050030-b010">10</xref>]. In addition, clade C HIV (predominant in sub-Saharan Africa) may be more susceptible to the evolution of a tenofovir resistance mutation (the K65R mutation) [<xref ref-type="bibr" rid="pmed-0050030-b011">11</xref>].</p>
    </sec>
    <sec id="s4">
      <title>Strengths and Limitations of the New Study</title>
      <p>This new report [<xref ref-type="bibr" rid="pmed-0050030-b007">7</xref>] represents the culmination of a series of recent studies specifically designed to guide and inform human clinical PrEP trials [<xref ref-type="bibr" rid="pmed-0050030-b005">5</xref>,<xref ref-type="bibr" rid="pmed-0050030-b006">6</xref>]. In addition, the new study shows protection from SHIV by intermittent dosing with tenofovir and FTC, a regimen that is closer to true PrEP than continuous daily dosing.</p>
      <p>The study had four weaknesses. First, it included only small numbers of animals. Second, nine out of the 18 controls used were historical in nature. Third, FTC and tenofovir doses chosen as human-equivalent were based on first-dose pharmacokinetics in a limited number of animals, and they represent higher drug exposures than seen in humans (FTC and tenofovir areas under the concentration-time curves in macaques were approximately 30% and 40% higher, respectively, than exposures in humans [<xref ref-type="bibr" rid="pmed-0050030-b012">12</xref>]). In addition, intracellular pharmacokinetics of the active agents also differ between macaques and humans [<xref ref-type="bibr" rid="pmed-0050030-b013">13–15</xref>]. Finally, complete protection from HIV acquisition was only observed with a subcutaneous tenofovir dose that provided concentrations greater than can be achieved with oral therapy [<xref ref-type="bibr" rid="pmed-0050030-b016">16</xref>].</p>
    </sec>
    <sec id="s5">
      <title>The Future</title>
      <p>These results highlight an exciting and potentially important use of ART to prevent sexual transmission of HIV [<xref ref-type="bibr" rid="pmed-0050030-b003">3</xref>], and offer further support for human clinical trials in progress or planned. Optimistic modeling experiments suggest an important role for PrEP in HIV prevention [<xref ref-type="bibr" rid="pmed-0050030-b017">17</xref>]. But the application of PrEP highlights a unique tension between prevention and treatment; widespread usage of ART for prevention in communities where ART for treatment is still being rationed might cause conflict [<xref ref-type="bibr" rid="pmed-0050030-b018">18</xref>]. Also, PrEP has the potential to accelerate transmitted drug resistance [<xref ref-type="bibr" rid="pmed-0050030-b009">9</xref>], thereby limiting the utility of drugs critical to combination ART. Human PrEP trials must address these concerns. One PrEP safety trial has been completed in women at high risk of acquiring HIV in Africa [<xref ref-type="bibr" rid="pmed-0050030-b019">19</xref>]; other current trials designed to measure PrEP safety and efficacy are summarized in <xref ref-type="table" rid="pmed-0050030-t001">Table 1</xref>. These PrEP trials will shine a light on the potential of ART for prevention, and help physicians to think more broadly about the public health implications of these life-saving drugs.</p>
      <table-wrap content-type="4col" id="pmed-0050030-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pmed.0050030.t001</object-id><label>Table 1</label><caption>
          <title>Current and Proposed Pre-Exposure Prophylaxis Trials, October 2007</title>
        </caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pmed.0050030.t001" xlink:type="simple"/><!-- <table frame="hsides" rules="groups"><colgroup><col id="tb1col1" align="left"/><col id="tb1col2" align="left"/><col id="tb1col3" align="left"/><col id="tb1col4" align="left"/></colgroup><thead><tr><td><bold>Study (Sponsor)</bold></td><td><bold>Study and Agent(s) (Dose)</bold></td><td><bold>Population (Target N)</bold></td><td><bold>Sites</bold></td></tr></thead><tbody><tr><td>US CDC-NCHSTP-4323</td><td>Phase II daily TDF or daily oral placebo</td><td>MSM ages 18 to 60 (400)</td><td>US (anticipated completion 2009)</td></tr><tr><td>US CDC-NCHSTP-4370</td><td>Phase II/III daily TDF or daily oral placebo</td><td>IDU ages 20 to 60 (2,000)</td><td>Thailand (anticipated completion 2008)</td></tr><tr><td>CDC-NCHSTP-4940; BOTUSA MB06</td><td>Phase III daily Truvada or daily oral placebo</td><td>Men and women ages 18 to 29 (1 ,200)</td><td>Botswana (anticipated completion 2010)</td></tr><tr><td>iPrEX (NIAID/BMGF)</td><td>Phase III daily Truvada or daily oral placebo</td><td>MSM ages 18 and up (3,000)</td><td>Peru, Ecuador, Brazil, Thailand, South Africa, US (anticipated completion 2011)</td></tr><tr><td>FHI (USAID)</td><td>Phase III daily Truvada or daily oral placebo</td><td>High-risk women ages 18 to 35 (3,900)</td><td>Kenya, Malawi, South Africa, Tanzania, Zimbabwe (study planned, no anticipated completion date yet)</td></tr><tr><td>Partners Study (BMGF)</td><td>Phase III daily TDF, daily Truvada, or daily oral placebo</td><td>Discordant heterosexual couples ages 18 to 60 (4,000)</td><td>Uganda, Kenya (study planned, no anticipated completion date yet)</td></tr><tr><td>VOICE/MTN 003 (NIAID)</td><td>Phase IIB safety and effectiveness of daily tenofovir gel (1&percnt;) or placebo gel, or daily TDF (300 mg), Truvada, or oral placebo</td><td>Nonpregnant premenopausal women ages 18 to 35 (2,400 oral, 1,600 gel)</td><td>South Africa, Zambia, Malawi, Uganda, Zimbabwe (study planned, no anticipated completion date yet)</td></tr></tbody></table> --><!-- <table-wrap-foot><fn><p>BMGF, Bill &amp; Melinda Gates Foundation; BOTUSA, the collaborative effort between the Botswana Ministry of Health, the US Centers for Disease Control and Prevention/Division of Tuberculosis Elimination, and the Global AIDS Program; FHI, Family Health International; IDU, injecting drug users; iPrEX, Andean MSM PrEP Trial; MSM, men who have sex with men; MTN, Microbicide Treatment Network; NIAID, US National Institute of Allergy and Infectious Disease; USAID, United States Agency for International Development; US CDC, United States Centers for Disease Control and Prevention; NCHSTP, National Center for HIV, STD, and TB Prevention; VOICE, Vaginal and Oral Interventions to Control the Epidemic.</p></fn></table-wrap-foot> --></table-wrap>
    </sec>
  </body>
  <back>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>ART</term>
          <def>
            <p>antiretroviral therapy</p>
          </def>
        </def-item>
        <def-item>
          <term>FTC</term>
          <def>
            <p>emtricitabine</p>
          </def>
        </def-item>
        <def-item>
          <term>PrEP</term>
          <def>
            <p>pre-exposure prophylaxis</p>
          </def>
        </def-item>
        <def-item>
          <term>SHIV</term>
          <def>
            <p>simian HIV</p>
          </def>
        </def-item>
        <def-item>
          <term>TDF</term>
          <def>
            <p>tenofovir disoproxil fumarate</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <ref-list>
      <title>References</title>
      <ref id="pmed-0050030-b001">
        <label>1</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Palella</surname><given-names>FJ</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Delaney</surname><given-names>KM</given-names></name><name name-style="western"><surname>Moorman</surname><given-names>AC</given-names></name><name name-style="western"><surname>Loveless</surname><given-names>MO</given-names></name><name name-style="western"><surname>Fuhrer</surname><given-names>J</given-names></name><etal/></person-group>
					<year>1998</year>
					<article-title>Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.</article-title>
					<source>N Engl J Med</source>
					<volume>338</volume>
					<fpage>853</fpage>
					<lpage>860</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0050030-b002">
        <label>2</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Cardo</surname><given-names>DM</given-names></name><name name-style="western"><surname>Culver</surname><given-names>DH</given-names></name><name name-style="western"><surname>Ciesielski</surname><given-names>CA</given-names></name><name name-style="western"><surname>Srivastava</surname><given-names>PU</given-names></name><name name-style="western"><surname>Marcus</surname><given-names>R</given-names></name><etal/></person-group>
					<year>1997</year>
					<article-title>A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group.</article-title>
					<source>N Engl J Med</source>
					<volume>337</volume>
					<fpage>1485</fpage>
					<lpage>1490</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0050030-b003">
        <label>3</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Cohen</surname><given-names>MS</given-names></name><name name-style="western"><surname>Gay</surname><given-names>C</given-names></name><name name-style="western"><surname>Kashuba</surname><given-names>AD</given-names></name><name name-style="western"><surname>Blower</surname><given-names>S</given-names></name><name name-style="western"><surname>Paxton</surname><given-names>L</given-names></name></person-group>
					<year>2007</year>
					<article-title>Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1.</article-title>
					<source>Ann Intern Med</source>
					<volume>146</volume>
					<fpage>591</fpage>
					<lpage>601</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0050030-b004">
        <label>4</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Fowler</surname><given-names>MG</given-names></name><name name-style="western"><surname>Lampe</surname><given-names>MA</given-names></name><name name-style="western"><surname>Jamieson</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Kourtis</surname><given-names>AP</given-names></name><name name-style="western"><surname>Rogers</surname><given-names>MF</given-names></name></person-group>
					<year>2007</year>
					<article-title>Reducing the risk of mother-to-child human immunodeficiency virus transmission: past successes, current progress and challenges, and future directions.</article-title>
					<source>Am J Obstet Gynecol</source>
					<volume>197</volume>
					<fpage>S3</fpage>
					<lpage>S9</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0050030-b005">
        <label>5</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Otten</surname><given-names>RA</given-names></name><name name-style="western"><surname>Adams</surname><given-names>DR</given-names></name><name name-style="western"><surname>Kim</surname><given-names>CN</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>E</given-names></name><name name-style="western"><surname>Pullium</surname><given-names>JK</given-names></name><etal/></person-group>
					<year>2005</year>
					<article-title>Multiple vaginal exposures to low doses of R5 simian-human immunodeficiency virus: strategy to study HIV preclinical interventions in nonhuman primates.</article-title>
					<source>J Infect Dis</source>
					<volume>191</volume>
					<fpage>164</fpage>
					<lpage>173</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0050030-b006">
        <label>6</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Subbarao</surname><given-names>S</given-names></name><name name-style="western"><surname>Otten</surname><given-names>RA</given-names></name><name name-style="western"><surname>Ramos</surname><given-names>A</given-names></name><name name-style="western"><surname>Kim</surname><given-names>C</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>E</given-names></name><etal/></person-group>
					<year>2006</year>
					<article-title>Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges.</article-title>
					<source>J Infect Dis</source>
					<volume>194</volume>
					<fpage>904</fpage>
					<lpage>911</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0050030-b007">
        <label>7</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>García-Lerma</surname><given-names>JG</given-names></name><name name-style="western"><surname>Otten</surname><given-names>RA</given-names></name><name name-style="western"><surname>Qari</surname><given-names>SH</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>E</given-names></name><name name-style="western"><surname>Cong</surname><given-names>M</given-names></name><etal/></person-group>
					<year>2008</year>
					<article-title>Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir.</article-title>
					<source>PLoS Med</source>
					<volume>5</volume>
					<fpage>e28</fpage>
					<comment>doi:<ext-link ext-link-type="doi" xlink:href="http://dx.doi.org/10.1371/journal.pmed.0050028" xlink:type="simple">10.1371/journal.pmed.0050028</ext-link></comment>
				</element-citation>
      </ref>
      <ref id="pmed-0050030-b008">
        <label>8</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Brenchley</surname><given-names>JM</given-names></name><name name-style="western"><surname>Schacker</surname><given-names>TW</given-names></name><name name-style="western"><surname>Ruff</surname><given-names>LE</given-names></name><name name-style="western"><surname>Price</surname><given-names>DA</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>JH</given-names></name><etal/></person-group>
					<year>2004</year>
					<article-title>CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract.</article-title>
					<source>J Exp Med</source>
					<volume>200</volume>
					<fpage>749</fpage>
					<lpage>759</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0050030-b009">
        <label>9</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Booth</surname><given-names>CL</given-names></name><name name-style="western"><surname>Geretti</surname><given-names>AM</given-names></name></person-group>
					<year>2007</year>
					<article-title>Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection.</article-title>
					<source>J Antimicrob Chemother</source>
					<volume>59</volume>
					<fpage>1047</fpage>
					<lpage>1056</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0050030-b010">
        <label>10</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Ferradini</surname><given-names>L</given-names></name><name name-style="western"><surname>Jeannin</surname><given-names>A</given-names></name><name name-style="western"><surname>Pinoges</surname><given-names>L</given-names></name><name name-style="western"><surname>Izopet</surname><given-names>J</given-names></name><name name-style="western"><surname>Odhiambo</surname><given-names>D</given-names></name><etal/></person-group>
					<year>2006</year>
					<article-title>Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment.</article-title>
					<source>Lancet</source>
					<volume>367</volume>
					<fpage>1335</fpage>
					<lpage>1342</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0050030-b011">
        <label>11</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Brenner</surname><given-names>BG</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>M</given-names></name><name name-style="western"><surname>Doualla-Bell</surname><given-names>F</given-names></name><name name-style="western"><surname>Moisi</surname><given-names>DD</given-names></name><name name-style="western"><surname>Ntemgwa</surname><given-names>M</given-names></name><etal/></person-group>
					<year>2006</year>
					<article-title>HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture.</article-title>
					<source>AIDS</source>
					<volume>20</volume>
					<fpage>F9</fpage>
					<lpage>F13</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0050030-b012">
        <label>12</label>
        <element-citation publication-type="other" xlink:type="simple">
					<collab xlink:type="simple">Gilead Sciences</collab>
					<year>2007</year>
					<article-title>Truvada package insert. 21-752-GS-20.</article-title>
					<comment>Available: <ext-link ext-link-type="uri" xlink:href="http://www.gilead.com/pdf/truvada_pi.pdf" xlink:type="simple">http://www.gilead.com/pdf/truvada_pi.pdf</ext-link>. Accessed 3 January 2008</comment>
				</element-citation>
      </ref>
      <ref id="pmed-0050030-b013">
        <label>13</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Wang</surname><given-names>LH</given-names></name><name name-style="western"><surname>Begley</surname><given-names>J</given-names></name><name name-style="western"><surname>St Claire</surname><given-names>RL</given-names><suffix>3rd</suffix></name><name name-style="western"><surname>Harris</surname><given-names>J</given-names></name><name name-style="western"><surname>Wakeford</surname><given-names>C</given-names></name><etal/></person-group>
					<year>2004</year>
					<article-title>Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection.</article-title>
					<source>AIDS Res Hum Retroviruses</source>
					<volume>20</volume>
					<fpage>1173</fpage>
					<lpage>1182</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0050030-b014">
        <label>14</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Hawkins</surname><given-names>T</given-names></name><name name-style="western"><surname>Veikley</surname><given-names>W</given-names></name><name name-style="western"><surname>St Claire</surname><given-names>RL</given-names><suffix>3rd</suffix></name><name name-style="western"><surname>Guyer</surname><given-names>B</given-names></name><name name-style="western"><surname>Clark</surname><given-names>N</given-names></name><etal/></person-group>
					<year>2005</year>
					<article-title>Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens.</article-title>
					<source>J Acquir Immune Defic Syndr</source>
					<volume>39</volume>
					<fpage>406</fpage>
					<lpage>411</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0050030-b015">
        <label>15</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>King</surname><given-names>T</given-names></name><name name-style="western"><surname>Bushman</surname><given-names>L</given-names></name><name name-style="western"><surname>Kiser</surname><given-names>J</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>PL</given-names></name><name name-style="western"><surname>Ray</surname><given-names>M</given-names></name><etal/></person-group>
					<year>2006</year>
					<article-title>Liquid chromatography-tandem mass spectrometric determination of tenofovir-diphosphate in human peripheral blood mononuclear cells.</article-title>
					<source>J Chromatogr B Analyt Technol Biomed Life Sci</source>
					<volume>843</volume>
					<fpage>147</fpage>
					<lpage>156</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0050030-b016">
        <label>16</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Van Rompay</surname><given-names>KK</given-names></name><name name-style="western"><surname>Brignolo</surname><given-names>LL</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Jerome</surname><given-names>C</given-names></name><name name-style="western"><surname>Tarara</surname><given-names>R</given-names></name><etal/></person-group>
					<year>2004</year>
					<article-title>Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy) propyl]adenine (tenofovir) to newborn and infant rhesus macaques.</article-title>
					<source>Antimicrob Agents Chemother</source>
					<volume>48</volume>
					<fpage>1469</fpage>
					<lpage>1487</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0050030-b017">
        <label>17</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Abbas</surname><given-names>UL</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>RM</given-names></name><name name-style="western"><surname>Mellors</surname><given-names>JW</given-names></name></person-group>
					<year>2007</year>
					<article-title>Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings.</article-title>
					<source>PLoS ONE</source>
					<volume>2</volume>
					<fpage>e875</fpage>
					<comment>doi:<ext-link ext-link-type="doi" xlink:href="http://dx.doi.org/10.1371/journal.pone.0000875" xlink:type="simple">10.1371/journal.pone.0000875</ext-link></comment>
				</element-citation>
      </ref>
      <ref id="pmed-0050030-b018">
        <label>18</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Grant</surname><given-names>RM</given-names></name><name name-style="western"><surname>Buchbinder</surname><given-names>S</given-names></name><name name-style="western"><surname>Cates</surname><given-names>W</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Clarke</surname><given-names>E</given-names></name><name name-style="western"><surname>Coates</surname><given-names>T</given-names></name><etal/></person-group>
					<year>2005</year>
					<article-title>AIDS. Promote HIV chemoprophylaxis research, don't prevent it.</article-title>
					<source>Science</source>
					<volume>309</volume>
					<fpage>2170</fpage>
					<lpage>2171</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0050030-b019">
        <label>19</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Peterson</surname><given-names>L</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>D</given-names></name><name name-style="western"><surname>Roddy</surname><given-names>R</given-names></name><name name-style="western"><surname>Belai</surname><given-names>G</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>P</given-names></name><etal/></person-group>
					<year>2007</year>
					<article-title>Tenofovir disoproxil fumarate for prevention of HIV infection in women: A phase 2, double-blind, randomized, placebo-controlled trial.</article-title>
					<source>PLOS Clin Trial</source>
					<volume>2</volume>
					<fpage>e27</fpage>
					<comment>doi:<ext-link ext-link-type="doi" xlink:href="http://dx.doi.org/10.1371/journal.pctr.0020027" xlink:type="simple">10.1371/journal.pctr.0020027</ext-link></comment>
				</element-citation>
      </ref>
    </ref-list>
    
  </back>
</article>